Antibody Persistence 1–5 Years Following Vaccination With MenAfriVac in African Children Vaccinated at 12–23 Months of Age

• Published in: Clinical infectious diseases Vol. 61; no. suppl_5; pp. S514 - S520
• Main Authors: Tapia, Milagritos D., Findlow, Helen, Idoko, Olubukola T., Preziosi, Marie-Pierre, Kulkarni, Prasad S., Enwere, Godwin C., Elie, Cheryl, Parulekar, Varsha, Sow, Samba O., Haidara, Fadima Cheick, Diallo, Fatoumata, Doumbia, Moussa, Akinsola, Adebayo K., Adegbola, Richard A., Kampmann, Beate, Chaumont, Julie, Martellet, Lionel, Marchetti, Elisa, Viviani, Simonetta, Tang, Yuxiao, Plikaytis, Brian D., LaForce, F. Marc, Carlone, George, Borrow, Ray
• Format: Journal Article
• Language: English
• Published: United States Oxford University Press 15.11.2015
• Subjects: Africa; Animals; Antibodies, Bacterial - blood; Blood Bactericidal Activity; Complement System Proteins; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Humans; Immunization; Immunoassay; Immunoglobulin G - blood; Infant; Male; Meningitis; Meningococcal Vaccines - administration & dosage; Meningococcal Vaccines - immunology; Preschool children; Rabbits; SEROLOGIC AND SAFETY STUDIES OF A GROUP A MENINGOCOCCAL CONJUGATE VACCINE; The Meningitis Vaccine Project: The Development, Licensure, , and Impact of a New Group a Meningococcal Conjugate Vaccine for Africa; Time Factors; Vaccines; Africa; MenAfriVac; group A meningococcal conjugate vaccine; African meningitis belt; antibody persistence
• ISSN: 1058-4838; 1537-6591
• DOI: 10.1093/cid/civ672

Background. Following mass vaccination campaigns in the African meningitis belt with group A meningococcal conjugate vaccine, MenAfriVac (PsA-TT), disease due to group A meningococci has nearly disappeared. Antibody persistence in healthy African toddlers was investigated. Methods. African children vaccinated at 12–23 months of age with PsA-TT were followed for evaluation of antibody persistence up to 5 years after primary vaccination. Antibody persistence was evaluated by measuring group A serum bactericidal antibody (SBA) with rabbit complement and by a group A–specific IgG enzyme-linked immunosorbent assay (ELISA). Results. Group A antibodies measured by SBA and ELISA were shown to decline in the year following vaccination and plateaued at levels significantly above baseline for up to 5 years following primary vaccination. Conclusions. A single dose of PsA-TT induces long-term sustained levels of group A meningococcal antibodies for up to 5 years after vaccination. Clinical Trials Registration. ISRTCN78147026.